Results 181 to 190 of about 21,820 (216)

Ceftazidime/avibactam serum concentration in patients on ECMO

Journal of Antimicrobial Chemotherapy
Abstract Objectives The use of extracorporeal membrane oxygenation (ECMO) may alter blood levels of several drugs, including antibiotics, leading to under dosing of these drugs and thus to potential treatment failure.
Anaïs Curtiaud, Matthieu Petit, Juliette Chommeloux, Marc Pineton de Chambrun, Guillaume Hekimian, Matthieu Schmidt, Alain Combes, Charles-Edouard Luyt   +7 more
openaire   +2 more sources

Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation

Transplantation Proceedings, 2020
After lung transplantation (LTx), infections caused by multidrug-resistant (MDR) bacteria are frequent and difficult to treat. Some new antibiotics seem to be effective in treating these infections.We describe our experience in treatment of Klebsiella pneumoniae MDR and Pseudomonas aeruginosa MDR infections with ceftazidime-avibactam (CEF-AVI) and ...
Amore D., Pecoraro Y., Carillo C., Russo G., Poggi C., Anile M., Pagini A., Bassi M., Cagnetti S., Mottola E., D'Agostino F. G., Vannucci J., Mantovani S., Pugliese F., De Giacomo T., Rendina E. A., Venuta F., Diso D.   +17 more
openaire   +2 more sources

Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections

Expert Opinion on Pharmacotherapy, 2016
The treatment of complicated intra-abdominal infections (cIAI) is increasingly challenging due to increased resistance of Gram-negative organisms. These multidrug resistant organisms lead to an increase in morbidity and mortality. This has led to renewed interest in use of older β-lactam antibiotics in combination with newer β-lactamase inhibitors ...
Sara A, Buckman, Tamara, Krekel, Anouk E, Muller, John E, Mazuski   +3 more
openaire   +2 more sources

Therapeutic insights: Use of ceftazidime‐avibactam in pediatric patients

Pediatrics International
Abstract Background The increasing worldwide prevalence of multidrug‐resistant (MDR) bacteria underscores the pressing demand for innovative therapeutic solutions. Ceftazidime‐avibactam (CAZ‐AVI) represents a promising new drug combination that has received approval for specific infection types.
Özge Metin Akcan, Mustafa Gençeli, Talha Üstüntaş, Abdullah Akkuş, Sevgi Pekcan, Metin Doğan   +5 more
openaire   +2 more sources

Safety evaluation of ceftazidime/avibactam based on FAERS database

Infection
To explore adverse event (AE) signals of Ceftazidime/avibactam (CZA) based on the FDA Adverse Event Reporting System (FAERS) database.AE reports primarily associated with CZA were retrieved from the FAERS database from the second quarter of 2015 to the second quarter of 2023.
Xiuhong, Zhang, Ying, Jiang, Yating, Guo, Wenbo, Zhou, Weizhen, Qiao, Haohao, Zhu, Zhigang, Qi   +6 more
openaire   +2 more sources

REALITY DATA ON THE USE AND EFFECTIVENESS OF CEFTAZIDIME - AVIBACTAM

Tạp chí Truyền nhiễm Việt Nam
Ceftazidime - avibactam (CAZ-AVI), a novel cephalosporin, has proven activity against multidrugresistant Enterobacterales and P. aeruginosa, and it has only been used in Vietnam in recent years.Objectives: This study aimed to describe the usage pattern and treatment effectiveness of CAZ-AVI.
Van Dao Nguyen, Thanh Hai Duong
openaire   +1 more source

Studying ceftazidime-avibactam in selected populations

The Lancet Infectious Diseases, 2016
Florian M E, Wagenlehner, Kurt G, Naber
openaire   +2 more sources

Ceftazidime–Avibactam Sodium

2021
openaire   +1 more source

Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview

Antimicrobial Agents and Chemotherapy, 2022
André Birgy, Olivier Tenaillon, Hervé Jacquier   +2 more
exaly  

Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run

Journal of Antimicrobial Chemotherapy, 2023
Federico Pèa, Milo Gatti
exaly